Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Hematologic Neoplasms × tafasitamab × Clear all

Phase

Status

Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Hematologic Neoplasms 1

Interventions

fludarabine 6 Cyclophosphamide 5 fludarabine phosphate 4 Whole-Body Irradiation 4 angiotensin I (1-7) 3 pembrolizumab 2 itacitinib 2 Tacrolimus 2 Olanzapine 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 CTLA-4 Antigen 2 Busulfan 2 Brentuximab Vedotin 2 Bendamustine Hydrochloride 2 AP 1903 reagent 2 tazemetostat 1 tafasitamab 1 ruxolitinib 1 pomalidomide 1 ofatumumab 1 merphos 1 lopinavir-ritonavir drug combination 1 ivosidenib 1 ibrutinib 1 fedratinib 1 enasidenib 1 daratumumab 1 ceritinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡